Circulatory system

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Wednesday, October 11, 2023

Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).
  • Findings also demonstrated treatment with Zeposia resulted in low rates of progression independent relapse activity (PIRA) and relapse-associated worsening (RAW), key drivers of disease progression and permanent disability in multiple sclerosis.
  • “These new data underscore Zeposia’s potential to delay disease progression and improve cognitive function, especially in individuals with early relapsing multiple sclerosis,” said Roland Chen, MD , senior vice president and head, Immunology, Cardiovascular and Neuroscience Development, Bristol Myers Squibb.
  • “With our focus on transformational science, we remain deeply committed to finding solutions to elevate care for the multiple sclerosis community.”
    Bristol Myers Squibb thanks the patients and investigators who participated in the Zeposia clinical trials.

The Inner Circle Acknowledges, Abraham Bornstein as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields

Retrieved on: 
Friday, October 13, 2023

NEW YORK, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Abraham Bornstein is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields.

Key Points: 
  • NEW YORK, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Abraham Bornstein is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields.
  • Dr. Bornstein pursued higher education at Boston University where he earned a Bachelor of Arts degree in Biology in 1969.
  • He then attended Tufts University School of Medicine in 1973 obtaining a Doctor of Medicine degree in 1973.
  • He has received many accolades during his career, including multiple teaching awards from Stanford Hospital and Practice.

Adiso Therapeutics Expands Board of Directors with Appointment of Robert Lisicki

Retrieved on: 
Thursday, October 12, 2023

CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.

Key Points: 
  • CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.
  • "The Adiso Board and I are very pleased to welcome Robert Lisicki.
  • Rob is an accomplished biopharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition," said Jason Dinges, Morningside Technology Advisory and Adiso Board Member.
  • Mr. Lisicki has nearly 30 years of experience in the pharma/biotech sector, most recently serving as Chief Executive Office and Board Member of InCarda Therapeutics.

MCRA Assists Attune Medical on FDA De Novo Marketing Authorization for ensoETM™ Esophageal Thermal Regulating Device

Retrieved on: 
Wednesday, October 11, 2023

This new marketing authorization establishes a new Product Code, expanding the classification of ensoETM as a temperature regulation device for esophageal protection during cardiac ablation procedures.

Key Points: 
  • This new marketing authorization establishes a new Product Code, expanding the classification of ensoETM as a temperature regulation device for esophageal protection during cardiac ablation procedures.
  • Attune Medical is the pioneer of using the esophageal space to manage temperature and received its first De Novo authorization in 2015.
  • MCRA's Cardiovascular Regulatory experts assisted Attune Medical through regulatory strategy, pre-submission and De Novo submission to the US FDA utilizing the totality of clinical data available.
  • Together, Attune Medical and MCRA were able to present FDA with a sound regulatory approach, clear framing of complex datasets and a compelling benefit-risk assessment.

Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs

Retrieved on: 
Friday, September 29, 2023

Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Key Points: 
  • Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
  • Stephane Degove, Atamyo CEO, will provide a corporate overview at two forthcoming conferences in October:
    Chardan's 7th Annual Genetic Medicines Conference, held in New York City:
    - Presentation on October 2, at 10:30 AM, in the Embassy room
    Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, on October 10-12, 2023:
    - Presentation on October 10, at 5:15pm, at the Rentschler ATMP Ballroom
    Two upcoming communications at the 28th Annual Congress of the World Muscle Society (3-7 October 2023 in Charleston, SC)
    • Oral Presentation by A. Brureau (Genethon), at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 282 at Ballroom C, on October 4, 2023, 17h15-18h15
    Natural history of limb girdle muscular dystrophy R9: one-year follow-up of a European cohort
    • Oral Presentation by J. Vissing (Copenhagen Neuromuscular Center, Rigshospitale) at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 283 at Ballroom C, on October 4, 2023, 17h15-18h15
    Two communications describing Atamyo’s LGMD programs will be presented at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) that will take place on October 24-27, 2023 in Brussel (Belgium):
    • Oral presentation by Nicolai Preisler, MD, Rigshospitalet, Copenhagen, during the Cardiovascular and muscular diseases session, on Friday October 27, 11h30-13h00 – Le BEL, Tour & Taxis
    Oral presentation on Atamyo’s LGMD-R9 program at the 2023 International Limb-Girdle Muscular Dystrophy Conference (28-29 October 2023, Washington DC)
    • Oral presentation by John Vissing, MD, Rigshospitalet, Copenhagen, during the Clinical Trials Updates (Part 1) Session, on October 29, 11h00am-12h10pm – Constitution Ballroom, Grand Hyatt

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

Retrieved on: 
Tuesday, September 26, 2023

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.
  • Hence, such factors drive the growth of the implantable medical devices market during the forecast period.
  • Detailed information on factors that will drive the growth of the implantable medical devices market between 2022 and 2027.
  • Growth of the implantable medical devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of implantable medical devices market vendors.

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

Retrieved on: 
Friday, September 8, 2023

BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.

Key Points: 
  • BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.
  • The abstract is to be presented by Professor of Interventional Radiology Vincent Vidal, M.D.
  • PhD, from the Aix-Marseille University and a Scientific Advisory Board Member of Microbot.
  • The team expressed their positive experiences and satisfaction from using the Company’s Robotic Surgery System.

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Retrieved on: 
Friday, September 8, 2023

IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.

Key Points: 
  • IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.
  • IceCure will be participating in the Tumor Ablation Hands-On Device Training with the ProSense cryoablation system.
  • This is a great opportunity for attendees to gain hands-on knowledge of IceCure's cryoablation device and to see the system's advantages.
  • Thanks to this grant, ten aspiring women interventional radiologists' abstracts were accepted and will receive sponsored congress registration, travel, and accommodation.

NeurAxis Highlights Strength of its Board of Directors

Retrieved on: 
Thursday, August 24, 2023

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.

Key Points: 
  • CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
  • “We are fortunate to have a board with a depth of experience in relevant areas to NeurAxis, including medical device commercialization, commercial insurance, and finance.
  • “We are excited to have this strength at the board level as we continue to develop and drive adoption of our IB Stim Therapy™,” concluded Mr. Carrico.
  • The Company’s Board of Directors includes:
    Ms. Keyser has more than 20 years of experience in executive roles in population health.

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

Retrieved on: 
Monday, August 21, 2023

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.
  • The Bristol Myers Squibb-Pfizer Alliance will also share an observational retrospective real-world study on the clinical impact of switching or continuation of Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF).
  • “This year’s ESC Congress provides the opportunity to present new data spanning our cardiovascular portfolio, reinforcing our ambition of bringing innovative and life-changing medicines to patients living with cardiovascular diseases,” said Roland Chen, MD, Senior Vice President and Head of Cardiovascular & Neuroscience Development, Global Drug Development.
  • Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at ESC Congress 2023 include: